#7 AND FINALLY ... WHY YOU SHOULD KEEP YOUR EYES ON TELIX...

#7 AND FINALLY ... WHY YOU SHOULD KEEP YOUR EYES ON TELIX (ASX:TLX)Shane Fitzgerlad fielded the question about why Monash was reducing its position in one of its best and biggest holdings, the pharmaceutical firm, Telix."It's one of the biggest stocks in the portfolio and we've been reducing the position," he said "We're basically taking profits as the share price has continued on the spectacular run."However their interest in Telix far from over. "When we look at Telix, there are some very, very big catalyst events coming up." Fitzgerlad said"On the 23rd of this month, the FDA has to finally say whether it's going to approve or not approve the prostate imaging. Given the way this has played out, there is almost no, no doubt whatsoever that the approval will be given."And at that point, Telix will become a revenue-generating biotech, which is quite a rare beast on the Australian stock market. "We think there's a lot of potential for more upside in this stock because we haven't even talked about the therapeutic modality that they have. So we have very high expectations going forward, but we continue to trim the position as it goes up to manage the risk in the portfolio."